Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
1 Apr 24
8-K
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
1 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Other Events
7 Mar 24
8-K
Other Events
10 Jan 24
S-8
Registration of securities for employees
5 Jan 24
10-Q
2023 Q3
Quarterly report
30 Oct 23
8-K
Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights
30 Oct 23
10-Q
2023 Q2
Quarterly report
31 Jul 23
8-K
Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights
31 Jul 23
8-K
BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population
25 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 23
8-K
Other Events
2 May 23
10-Q
2023 Q1
Quarterly report
2 May 23
8-K
Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights
2 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
Biomea Fusion Announces Proposed Public Offering of Common Stock
3 Apr 23
424B5
Prospectus supplement for primary offering
30 Mar 23
424B5
Prospectus supplement for primary offering
29 Mar 23
8-K
Regulation FD Disclosure
28 Mar 23
10-K
2022 FY
Annual report
28 Mar 23
8-K
Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
28 Mar 23
8-K
Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones
12 Jan 23
S-8
Registration of securities for employees
4 Jan 23
8-K
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes
16 Dec 22
8-K
Other Events
13 Dec 22
8-K
Entry into a Material Definitive Agreement
25 Nov 22
424B5
Prospectus supplement for primary offering
25 Nov 22
10-Q
2022 Q3
Quarterly report
7 Nov 22
8-K
Biomea Fusion Reports Third Quarter 2022 Financial Results and Business Highlights
7 Nov 22
8-K
Other Events
1 Nov 22
EFFECT
Notice of effectiveness
25 Oct 22
CORRESP
Correspondence with SEC
20 Oct 22
UPLOAD
Letter from SEC
19 Oct 22
8-K
Other Events
18 Oct 22
S-3
Shelf registration
14 Oct 22
8-K
Other Events
22 Sep 22
Latest ownership filings
SC 13G
STATE STREET CORP
10 Apr 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
Erdtmann Rainer M
12 Feb 24
SC 13G/A
Butler Thomas Andrew
12 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
12 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G
Laurion Capital Management LP
8 Feb 24
SC 13G
BlackRock Inc.
29 Jan 24
4
Thomas Andrew Butler
18 Jan 24
4
Rainer M Erdtmann
18 Jan 24
4
Franco Valle
18 Jan 24
4
Juan Pablo Frias
18 Jan 24
4
Rainer M Erdtmann
3 Jan 24
4
Franco Valle
1 Dec 23
4
Juan Pablo Frias
1 Sep 23
3
Juan Pablo Frias
1 Sep 23
4
Michael J.M. Hitchcock
16 Jun 23
4
Bihua Chen
16 Jun 23
4
Elizabeth Faust
16 Jun 23
4
Sumita Ray
16 Jun 23
4
ERIC AGUIAR
16 Jun 23
4
Franco Valle
2 Jun 23
4
Change in insider ownership
2 Jun 23
144
Notice of proposed sale of securities
19 May 23
4
Change in insider ownership
17 May 23
4
Change in insider ownership
10 May 23
SC 13G
FMR LLC
10 May 23
144
Notice of proposed sale of securities
27 Apr 23
4
Change in insider ownership
26 Apr 23
144
Notice of proposed sale of securities
20 Apr 23
4/A
Change in insider ownership (amended)
6 Apr 23
4
Change in insider ownership
6 Apr 23
SC 13D/A
Cormorant Global Healthcare Master Fund, LP
3 Apr 23
4
Bihua Chen
3 Apr 23
SC 13G
BAKER BROS. ADVISORS LP
14 Feb 23
SC 13G/A
Butler Thomas Andrew
10 Feb 23
SC 13G/A
Erdtmann Rainer M
10 Feb 23
5
Rainer M Erdtmann
10 Feb 23
4/A
Rainer M Erdtmann
10 Feb 23
SC 13G/A
JANUS HENDERSON GROUP PLC
10 Feb 23